X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/17/2864622/0/en/Allarity-Therapeutics-Receives-NASDAQ-Approved-Extension-to-Regain-Compliance-with-Nasdaq-Listing-Rule-5550-b-1.html
https://www.globenewswire.com/news-release/2024/04/04/2857867/0/en/Allarity-Therapeutics-Announces-1-for-20-Reverse-Stock-Split.html
https://www.globenewswire.com/news-release/2024/03/27/2853146/0/en/Allarity-Therapeutics-Makes-Strategic-Pivot-to-Focus-Solely-on-Accelerating-Stenoparib-Toward-Regulatory-Approval-in-Advanced-Recurrent-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2024/03/25/2851509/0/en/Allarity-Therapeutics-Receives-Extension-from-Nasdaq-Hearings-Panel-to-Regain-Compliance-with-Listing-Rules-5550-a-2-and-5550-b-1.html
https://www.globenewswire.com/news-release/2024/03/08/2843041/0/en/Allarity-Therapeutics-Reports-Full-Year-2023-Financial-Results-and-Provides-a-Business-Update.html
https://www.globenewswire.com//news-release/2024/02/28/2836723/0/en/Allarity-Therapeutics-to-Present-at-Biomarkers-2024.html
https://endpts.com/novartis-ends-license-agreement-for-cancer-drug-with-allarity-therapeutics-for-lack-of-payment/
https://www.fiercebiotech.com/biotech/amid-ceo-turmoil-allarity-loses-rights-novartis-cancer-drug-over-missed-payments
https://www.globenewswire.com//news-release/2023/12/12/2794551/0/en/Allarity-Therapeutics-Announces-Thomas-Jensen-as-Interim-CEO-and-Appointment-of-Jeremy-R-Graff-PhD-as-Key-Executive-Advisor.html
https://www.globenewswire.com/news-release/2023/12/05/2790791/0/en/Allarity-s-Early-Phase-2-Stenoparib-Data-Indicates-Clinical-Benefit-in-Women-with-Advanced-Ovarian-Cancer-Selected-with-DRP-Companion-Diagnostic.html
Market Place
Share 
